Studies to Enhance FDA Communications Addressing Biosimilar Drug Products: Focus Groups with Patients

Data to Support Drug Product Communications

Confirmation Email

Studies to Enhance FDA Communications Addressing Biosimilar Drug Products: Focus Groups with Patients

OMB: 0910-0695

Document [docx]
Download: docx | pdf

CONFIRMATION EMAIL


OMB Control No. 0910-0695

Expiration Date: 02/28/2021





Hi [NAME],


Thank you so much for taking the time to speak with me regarding the online focus groups we are conducting next week!


You are scheduled for a 90-minute online focus group on [Date, Time, Time Zone].  During the session, we will ask you to share your thoughts and experiences about some of the medicines we discussed during our call, review health-related materials, and provide feedback on what you are viewing. You will need to be seated at a computer with a webcam in order to participate. Please have a list of your prescription medications ready for the group. Within two weeks of your participation, you will receive your payment through your preferred method, which you will indicate at the bottom of your consent form.


Any time before your session, please use the weblink below to access our virtual consent form.  After reviewing the information on the form, please scroll to the bottom, type in your name and the date, and click the "Finish" button to complete the form. You must complete the consent form prior to being able to participate and receive payment.


Link to consent form: [URL]



You will be logging into the focus group using the FocusVision Intervu platform. You will receive a separate email from FocusVision InterVu with instructions on how to log in to the online focus group.


Please let me know if you have any questions.  We look forward to your participation!



Yours in Service,

Naomi Rissinger | Research Associate

T: 717-963-8638 | M: 717-343-0721

File Typeapplication/vnd.openxmlformats-officedocument.wordprocessingml.document
AuthorJulie Brown
File Modified0000-00-00
File Created2021-01-16

© 2024 OMB.report | Privacy Policy